Parnell has developed a complete Osteoarthritis Management Program that combines ZYDAX® and GLYDE® with a world-first client education tool called iKAM.
This end-to-end solution is an extremely innovative business management tool that is coupled with best-in-class products to deliver optimal health outcomes to dogs, enhance the emotional bond with owners by improving quality of life and delivering a revenue stream to vet clinics. iKAM is an innovative client education app on an iPad.
The iKAM app educates dog owners about osteoarthritis and empowers them to proactively improve their dog’s quality of life. Dog owners simply navigate the app whilst in the waiting room prior to their veterinary consultation. iKAM is effective because it delivers a simple and consistent message in a timely manner that clients understand. iKAM features rich media content to educate dog owners about osteoarthritis and presents management options to improve their dog’s quality of life. ZYDAX Injection is a disease modifying osteoarthritis drug and is the leading innovation in osteoarthritis management.
ZYDAX is the only drug in its’ class that has been studied under gold standard FDA clinical trial conditions* and is manufactured in Parnell’s world-class manufacturing facility in Sydney.
GLYDE is a vet-only oral nutraceutical powder with a unique combination and therapeutic dose of glucosamine, chondroitin and green lipped mussel. You can experience the results first hand and unlock the potential in your practice by ordering your Experience Pack today.
The Experience Pack contains everything you need to get started: a three month supply of ZYDAX and GLYDE and an iPad loaded with the iKAM application.
If you are satisfied with the results at the end of the trial then simply tailor the supply volume for your practice and continue the monthly supply of ZYDAX and GLYDE and keep the iPad with iKAM^.
For more information or to order your 3 month Experience Pack contact Parnell on 1800 ZYDAX 2 (1800 993 292)
^Terms and conditions apply.
*Data on file. Parnell is conducting a series of pivotal studies for Zydax 100 to generate substantial evidence of effectiveness and safety for registration of Zydax 100 in USA and Europe.